These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33158765)

  • 1. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    Van den Bossche J; De Laere M; Deschepper K; Germonpré P; Valcke Y; Lamont J; Stein B; Van Camp K; Germonpré C; Nijs G; Roelant E; Anguille S; Lion E; Berneman Z
    PLoS One; 2024; 19(7):e0307204. PubMed ID: 39008481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
    Fennell DA; Ewings S; Ottensmeier C; Califano R; Hanna GG; Hill K; Danson S; Steele N; Nye M; Johnson L; Lord J; Middleton C; Szlosarek P; Chan S; Gaba A; Darlison L; Wells-Jordan P; Richards C; Poile C; Lester JF; Griffiths G;
    Lancet Oncol; 2021 Nov; 22(11):1530-1540. PubMed ID: 34656227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
    Lim E; Waller D; Lau K; Steele J; Pope A; Ali C; Bilancia R; Keni M; Popat S; O'Brien M; Tokaca N; Maskell N; Stadon L; Fennell D; Nelson L; Edwards J; Tenconi S; Socci L; Rintoul RC; Wood K; Stone A; Muthukumar D; Ingle C; Taylor P; Cove-Smith L; Califano R; Summers Y; Tasigiannopoulos Z; Bille A; Shah R; Fuller E; Macnair A; Shamash J; Mansy T; Milton R; Koh P; Ionescu AA; Treece S; Roy A; Middleton G; Kirk A; Harris RA; Ashton K; Warnes B; Bridgeman E; Joyce K; Mills N; Elliott D; Farrar N; Stokes E; Hughes V; Nicholson AG; Rogers CA;
    Lancet Respir Med; 2024 Jun; 12(6):457-466. PubMed ID: 38740044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D
    Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
    Sharkey AJ; O'Byrne KJ; Nakas A; Tenconi S; Fennell DA; Waller DA
    Lung Cancer; 2016 Oct; 100():5-13. PubMed ID: 27597274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Kim RY; Li Y; Marmarelis ME; Vachani A
    Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
    Kuribayashi K; Hirano J
    Anticancer Res; 2024 Oct; 44(10):4135-4145. PubMed ID: 39348972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
    Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
    Migliore M; Calvo D; Criscione A; Palmucci S; Fuccio Sanzà G; Caltabiano R; Spatola C; Privitera G; Aiello MM; Parra HS; Ciancio N; Di Maria G
    Future Oncol; 2015; 11(24 Suppl):19-22. PubMed ID: 26638918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
    Marulli G; Faccioli E; Bellini A; Mammana M; Rea F
    Expert Rev Respir Med; 2017 Aug; 11(8):649-660. PubMed ID: 28580813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
    Bylicki O; Guisier F; Scherpereel A; Daniel C; Swalduz A; Grolleau E; Bernardi M; Hominal S; Prevost JB; Pamart G; Marques MH; Cloarec N; Deshayes S; Raimbourg J; Veillon R; Oulkhouir Y; Audigier Valette C; Subtil F; Chouaïd C; Greillier L;
    Lung Cancer; 2024 Aug; 194():107866. PubMed ID: 38972083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.